Triggered Imaging in Glioblastoma Based on Clinical Outcome Evaluation Compared to Routine: a Feasibility Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: triggered imaging.
- Who it may be relevant to
- Registry conditions: Glioblastoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This is a feasibility randomized controlled trial comparing triggered imaging based on patient symptom self-reporting and performance-based measures with the existing imaging schedule.
Detailed description
Patients in intervention arm will be invited to complete weekly online symptom questionnaires. Responses will be evaluated and given a score, with higher scores reflecting 'red flag' symptoms or symptoms of a severity which meet pre-defined thresholds.
Interventions
- Diagnostic test triggered imaging
triggered imaging for symptoms as opposed to routine interval imaging
Primary outcome measures
- The primary outcomes are: - Number of patients willing to self-report symptoms on an online app - Number of patients willing to undertake cognitive testing - Number of complete symptom questionnaires and assessments - Number of fast track MRI [Time frame: From enrollment up to 12 months]
- The primary outcomes are: - Number of patients willing to self-report symptoms on an online app - Number of complete symptom questionnaires and assessments - Number of fast track MRI [Time frame: From enrollment up to 12 months]
Eligibility criteria
Inclusion criteria
i. Newly diagnosed glioblastoma (WHO grade IV) ii. Planned to undergo the Stupp treatment regimen iii. Aged 18-70 iv. To be treated at KCH and GSTT v. No MRI contraindications vi. Patients with internet access and an e-mail account
Exclusion criteria
i. Uncertainty of diagnosis ii. Deviation from the standard Stupp regimen iii. Patients participating in another interventional study iv. Unable to read and comprehend English language text v. Lack capacity at point of consent vi. WHO Performance status > 3 (Karnofsky score < 30)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
United Kingdom · 1 center
- KCH — London
Identifiers
NCT: NCT07634575 · KCH22-151